Australia's largest stock trading and investment forum Australia's #1 stock forum

TIS

Click for more information

0.00%

0.0¢ tissue therapies limited

EMA SAWP meeting, page-6

First 6 Last

Share
Profile

Follow
ajbhu

85 Posts.

2

07/05/15

22:38

Post #: 15238732
Share

Originally posted by CroMagnon ↑

ajbhu - you asked nicely and I shall answer:
Please note that I am impervious to mocking and take your request seriously.
By the way, I am not an expert.
This is just for starters and I am sure that other posters would like to add to it.

1) Come clean on all recent announcements and issue clarifications/corrections (including 2014).
And with clean I mean no fancy wordings, just straight talk.
Example1: What was withdrawn - the Application for ‘Marketing Approval’ or the ‘Application for Scientific Opinion’?
Example 2: Don’t invent fancy stories about investors – just say it as it is.
29/08/2012 - Private Placement to Strategic Investor
http://www.asx.com.au/asxpdf/20120829/pdf/428b871rg8jg87.pdf
http://www.asx.com.au/asxpdf/20120830/pdf/428cvdckk40nf9.pdf
http://www.asx.com.au/asxpdf/20120829/pdf/428b8h4t877srq.pdf
30/08/2012 – Section 708A(5)(e) Disclosure Notice
http://www.asx.com.au/asxpdf/20120830/pdf/428ct5tt9zshcz.pdf
Company failed to disclose in its original announcement (Private Placement to Strategic Investor) that Mr. Geoff Morris has been a paid consultant since mid 2011 (see http://www.asx.com.au/asxpdf/20110621/pdf/41zb206vc19nyy.pdf). He continues, as of recent (see http://www.asx.com.au/asxpdf/20150421/pdf/42y050bbr0l90c.pdf), to be a paid consultant.
More references:
http://www.asx.com.au/asxpdf/20140107/pdf/42m0hm3ykvmqpf.pdf
http://www.asx.com.au/asxpdf/20140408/pdf/42nw7vgrddq9v0.pdf
http://www.asx.com.au/asxpdf/20141023/pdf/42t3g87wnkqz8t.pdf
http://www.asx.com.au/asxpdf/20121122/pdf/42bcnpxql2q9h0.pdf
http://www.asx.com.au/asxpdf/20111202/pdf/4230xvhxmt2hj1.pdf
Example 3: Misleading info about VitroGro ECM: Clinical Effectiveness
http://www.asx.com.au/asxpdf/20150204/pdf/42wdg0k054gd7p.pdf
The inclusion of this trial without any reference to date/time makes it look like a recent trial when in fact it was done many many years ago. The reference to [11] points to the publication, in 2013, of the above referenced trial results.
Original announcement:
7/01/2010 http://www.asx.com.au/asxpdf/20100107/pdf/31n2gjslgkq9vy.pdf
13/10/2010 http://www.asx.com.au/asxpdf/20101013/pdf/31t324tq2hwn7k.pdf
14/07/2011 http://www.asx.com.au/asxpdf/20110714/pdf/41zrp771cpf39z.pdf
11/11/2011 http://www.asx.com.au/asxpdf/20111111/pdf/422gf8kghlw1mm.pdf
No need to say more ….

2) Come clean on all R&D related items including, but not limited to, the current applicable agreement(s) with QUT. Put a stop referring to patents and/or know-how the company does not own.
Example 1: Come clean on what IP is owned/attributable to the company and what to QUT.
Who, as a company employee, was involved in Government/State Research grants?
Have there been any benefits, in IP terms, attributable to the company?
Example 2: The company does not own any patents as implied below:
13/01/2009 - VitroGro Patent Granted in USA http://www.asx.com.au/asxpdf/20090113/pdf/31fjz60q3g52r8.pdf
.........
12/10/2010 Third VitroGro Patent Granted in Australia
http://www.asx.com.au/asxpdf/20101012/pdf/31t1t44wcxkq76.pdf

3) Put the company in an extended trading halt and renegotiate with QUT the IP transfer and R&D agreements. This is an absolute must and should take precedence over all other following items.
If no agreement can be reached put the company into administration (as a last resort).

4) Sack the R&D Manager and use the Patent lawyer’s she has been using in a more direct fashion.

5) Sack (or reduce to the absolute necessary minimum) the European sales team and ask our European partners – Quintiles, Movianto, …. - to fill the void (if there is one to fill).

6) Amend the Company Equity Option Plan. Make it applicable only for company employee’s (minimum 12+ month employment). Stop rewarding non-company employees/researchers/students/etc. for work that is not beneficial for the company. Remember: Tissue Therapies is not a charity organization.

And so on and on and on ……

And last, but not least, Fix-up the website and stop being on the economic side of the truth.
In this day and age of Google it is advisable to stay in close touch with the truth.
Sadly, Prof. Harding and Prod Baxter have been removed as Scientific Advisors.
Do not regurgitate over-and over-again an outdated trial.

Expand

Good. I will read deeply and with attention your hints.
With the IP, it is a must to transfer all patents on Tissue name.

TIS Price at posting: 8.9¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

ADD

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

RSG

Resolute shares bounce back as second payment made to Mali government to secure workers' release

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

HotCopper Highlights: Your most watched stocks for Week 48, 2024

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

There are more pages in this discussion • 2 more messages in this thread...

First 6 Last

Add TIS (ASX) to my watchlist